In patients who are found not to carry a founder mutation, we perform full sequencing using gene panels including BRCA1, BRCA2, CHEK2, and PALB2 in breast cancer cases with familial clustering of this cancer and/or in patients with early onset disease (diagnosed at age 45 or below). This evidence concerns the gene CHEK2 and breast carcinoma.